A Pilot Study to Evaluate the Safety and Efficacy of Aprepitant in Combination With Dolasetron and Dexamethasone for the Prevention of Nausea and Vomiting Following Oxaliplatin-containing Regimen Which Includes 5-FU
Phase of Trial: Phase III
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone; Dolasetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 14 Sep 2015 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
- 14 Nov 2007 New trial record.